Radiation plus immunotherapy for liver cancer
Part of Cancer, Digestive system clinical trials.
This early-phase trial tests a treatment plan that combines focused radiation with two medicines—an immunotherapy drug and an anti-angiogenesis drug—to treat hepatocellular carcinoma (liver cancer). It may help shrink tumors or control disease when surgery or ablation can’t be used, and when systemic (whole-body) treatment is needed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have hepatocellular carcinoma (HCC), a type of liver cancer.
- Your liver cancer can’t be treated with curative-intent surgery or ablation (for example, because of tumor size/extent, other health problems, or technical limits).
- Your doctors believe you need systemic therapy (treatment that works through the body, not just a local procedure).
- You are willing and able to take the trial’s radiation and medicine schedule as directed.
- There are no listed exclusion criteria for this trial here, but you must still be medically eligible after screening.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs (atezolizumab and bevacizumab) plus a targeted radiation treatment (Y-90 radioembolization) for people with liver cancer who are waiting for a liver transplant. The goal is to see if this treatment can help control the cancer and improve transplant outcomes.
This trial tests a combination of two immunotherapy drugs (atezolizumab and bevacizumab) with or without targeted radiation therapy for liver cancer that has invaded the major blood vessels of the liver. The goal is to see if adding radiation helps shrink tumors or slow the disease.
This trial tests adding two immunotherapy and anti-angiogenesis drugs (atezolizumab and bevacizumab) to standard photon radiation for people with liver cancer that cannot be surgically removed. It aims to see if this combination can shrink tumors and improve outcomes.
This trial studies how well atezolizumab and bevacizumab work together with radiation to treat advanced hepatocellular carcinoma (liver cancer) that has spread into the portal vein. It may help shrink or control tumors and improve outcomes, but you must meet several safety and cancer-location criteria.
This trial tests a combination of targeted radiation (SBRT) and immunotherapy for people with small liver cancers that have come back or are still present after prior treatment. It aims to see if this approach can better control the cancer without using heavy chemotherapy.
This trial tests a combination of radiation (SBRT), an immunotherapy drug (PD-L1 inhibitor), and a targeted therapy (lenvatinib) for people with liver cancer that has spread to abdominal lymph nodes. It may be an option if you haven't taken certain immunotherapies before or if your cancer progressed after them.
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.